Neutron activation of patients following boron neutron capture therapy of brain tumors at the High Flux Reactor (HFR) petten (EORTC trials 11961 and 11011)

Strahlentherapie und Onkologie

Volumn 181, Issue 12, 2005, Pages 774-782

  Wittig, Andrea ^a   Moss, Raymond L ^b   Stecher Rasmussen, Finn ^c,d   Appelman, Klaas ^d   Rassow, Jürgen ^a   Roca, Antoanetta ^b   Sauerwein, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Joint Research Center   (Netherlands)

^c NCT Physics   (Netherlands)

^d NUCLEAR RESEARCH AND CONSULTANCY GROUP NRG   (Netherlands)

Author keywords

ray spectrometry; Activation; Boron Neutron Capture Therapy (BNCT); Radiation protection

Indexed keywords

CALCIUM; CHLORINE; GOLD; INDIUM; SODIUM;

ARTICLE; BRAIN TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; GAMMA SPECTROMETRY; HUMAN; NEUTRON ACTIVATION ANALYSIS; NEUTRON CAPTURE THERAPY; RADIATION ABSORPTION; RADIATION DOSE; RADIATION PROTECTION; REACTOR;

BODY BURDEN; BORON NEUTRON CAPTURE THERAPY; BRAIN NEOPLASMS; ENVIRONMENTAL EXPOSURE; GERMANY; HUMANS; LINEAR ENERGY TRANSFER; NEUTRONS; NUCLEAR REACTORS; RADIATION DOSAGE; RADIATION MONITORING; RADIATION PROTECTION; RADIOISOTOPES; RELATIVE BIOLOGICAL EFFECTIVENESS; RISK ASSESSMENT; RISK FACTORS;

EID: 29144441991     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-005-1433-4     Document Type: Article

References (24)

1. Auberger T, Koester L, Knopf K, et al. In vivo neutron activation analysis of sodium and chlorine in tumor tissue after fast neutron therapy. Bull Cancer Radiother 1996;83:Suppl 1:37s-42s.
2. Bond GD, Theus RB, August LS, et al. In vivo activation analysis following neutron therapy in cancer patients. Med Phys 1976;3:148-249.
3. Erdtmann G, Soyka W. The g-lines of the radionuclides, vol 1, 2nd edn. Jül-1003-AC. Jülich: Zentralinstitut für analytische Chemie der Kernforschungsanlage Jülich, 1974.
4. Frost D, Michel L. Über die Zusatzdosis infolge Gewebeaktivierung bei der Therapie mit schnellen Elektronen sowie energiereicher Bremsstrahlung, Strahlentherapie 1967;132:228-45.
5. Heesters M, Molenaar W, Go GK. Radiotherapy in supratentorial gliomas. A study of 821 cases. Strahlenther Onkol 2003;179:606-14.
6. Hideghéty K, Sauerwein W, de Vries M, et al. Postoperative treatment of glioblastoma with Boron Neutron Capture Therapy at the European High Flux Reactor, Petten. Ann Oncol 1998:9:Suppl 2:129.
7. Hideghéty K, Sauerwein W, Haselsberger K, et al. Postoperative treatment of glioblastoma with BNCT at the Petten Irradiation facility (EORTC Protocol 11961). Strahlenther Onkol 1999;175:111-4.
8. ICRU Report 43. Determination of dose equivalents from external radiation sources - part 2. Bethesda: International Commission on Radiation Units and Measurements, 1988.
9. ICRU Report 46. Photon, electron, proton and neutron interaction data for body tissues. Bethesda: International Commission on Radiation Units and Measurements, 1992.
10. ICRP Publication 60 1990. Recommendations of the International Commission on Radiological Protection. Ann ICRP 1991, Oxford: Pergamon Press.
11. Lutterbach J, Sauerbrei W, Guttenberger R. Multivariate analysis of prognostic factors in patients with glioblastoma [Review]. Strahlenther Onkol 2003;179:219-32.
12. Moss RL, Aizawa O, Beynon D, et al. The requirements and development of neutron beams for neutron capture therapy of brain cancer. J Neurooncol 1997;33:27-40.
13. Moss RL, Rassow J, Finke E, et al. Radiological protection considerations during the treatment of glioblastoma patients by Boron Neutron Capture Therapy at the High Flux Reactor in Petten, The Netherlands. Radiological protection of patients in diagnostics and interventional radiology. Nuclear medicine and radiotherapy, IAEA-CSP-7/P. Vienna: International Atomic Energy Agency, 2001:609-13.
14. Moss RL, Stecher-Rasmussen F, Rassow J, et al. Procedural and practical applications of radiation measurements for BNCT at the HFR Petten. NIMB 2004;213:633-6.
15. Nieder C, Andratschke N, Wiedenmann N, et al. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome [Review]? Strahlenther Onkol 2004;180:401-7.
16. Nigg DW. Methods for radiation dose distribution analysis and treatment planning in boron neutron capture therapy. Int J Radiat Oncol Biol Phys 1994;28:1121-34.
17. Rassow J, Pöller F, Steinberg F, et al. Physical and tumor biological aspects and calculation model of dosage in boron neutron capture therapy (BNCT). Strahlenther Onkol 1993;169:7-17.
18. Sauerwein W. Principles and history of neutron capture therapy. Strahlenther Onkol 1993:169:1-6.
19. Sauerwein W, Hideghéty K, Rassow J, et al., and the EORTC BNCT Study Group. Boron neutron capture therapy: an interdisciplinary cooperation. IAEA-TECDOC-1223 "Current status of neutron capture therapy". Vienna: International Atomic Energy Agency, 2001:96-107.
20. Sauerwein W, Moss R, Rassow J, et al. Organisation and management of the first clinical trial of BNCT in Europe (EORTC Protocol 11961). Strahlenther Onkol 1999:175:108-11.
21. Sauerwein W, Zurlo A, on behalf of the EORTC Boron Neutron Capture Therapy Group. The EORTC Boron Neutron Capture Therapy (BNCT) Group: achievements and future projects. Eur J Cancer 2002:38:S31-4.
22. Seelmann-Eggebert W, Pfennig G, Münzel H, et al. Chart of the nuclides, 5th edn. Karlsruhe: Institut für Radiochemie des Kernforschungszentrums Karlsruhe, 1981.
23. Stuben G, Thews O, Pottgen C, et al. Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation. Strahlenther Onkol 2003;179:620-5.
24. Verbakel W, Sauerwein W, Hideghéty K, et al. Boron concentrations in brain during boron neutron capture therapy: in vivo measurements from the phase I trial EORTC 11961 using a gamma-ray telescope. Int J Radiat Oncol Biol Phys 2003;55:743-56.